Director/PDMR Shareholding

RNS Number : 4298I

C4X Discovery Holdings PLC

09 December 2015

 

C4X Discovery Holdings plc

("C4XD" or the "Company")

Director's Dealing

C4X Discovery Holdings plc (C4XD), a leader in rational drug discovery and design, announces that Clive Dix, Chairman of C4XD, purchased 50,000 ordinary shares of 1 pence each ("Ordinary Shares") on 8 December 2015 at a price of 77p per Ordinary Share.

Following this transaction, Clive has an interest in 691,250 Ordinary Shares, representing approximately 2.23 per cent of the Company's issued ordinary share capital.

For Further information please contact:

C4X Discovery Ltd

Clive Dix Executive Chairman                                                                                                    07912293832

Zeus Capital Ltd

Dan Bate                                                                                                                                              0161 831 1512

Dominic Wilson / Phil Walker                                                                                                     0203 829 5000

FTI Consulting

Matthew Cole                                                                                                                                   020 3727 1000

About C4X Discovery Ltd

C4XD (AIM: C4XD) is a Manchester-based company focused on optimising drug discovery and design. It was founded in 2008 as a spin-out from the University of Manchester. The company uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. Since C4XD's NMR technology shows what shapes active molecules prefer to adopt, it provides high-quality templates for rational drug discovery and design, and valuable conformational information for drug candidate optimisation. In addition, the data is generated faster and more reliably than standard techniques such as X-ray co-crystallography or molecular modelling. C4XD is using its technology in collaboration with the pharmaceutical industry and to build its own proprietary pipeline of high-value therapeutic candidates. For additional information please go to: www.c4xdiscovery.com

 

END

 

 

RDSEAPAPEEXSFFF